Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Dem Senate primary erupts in key state as...
Trump-backed candidate aims to pad GOP’s fragile House...
White House unleashes on Stacey Abrams in latest...
Ilhan Omar calls Trump an ‘unhinged lunatic,’ urges...
Former Virginia Gov Glenn Youngkin hints at political...
Trump’s apocalyptic Iran warning raises stakes for sweeping...
Graham eyes ‘down payment’ on Trump-backed SAVE Act...
Midterm alarm bells: Democrats face steep favorability deficit...
Democrat whose parents fled Iran moves to oust...
American journalist kidnapped in Iraq is set free,...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

FDA launches new AI-powered system to track drug and vaccine side effects nationwide

by admin March 11, 2026
March 11, 2026
FDA launches new AI-powered system to track drug and vaccine side effects nationwide

The Food and Drug Administration (FDA) rolled out a new platform, backed by artificial intelligence, that will streamline publicly accessible reporting of negative or unexpected health effects linked to medicines, vaccines, cosmetics, animal food and other consumer products.

The FDA Adverse Event Monitoring System (AEMS) began operation Tuesday and will consolidate outdated systems used to process millions of adverse event reports and produce results in real time for consumers to access online. 

‘The FDA’s fragmented adverse event systems have wasted taxpayer dollars and created large blind spots in our post-market surveillance,’ FDA Commissioner Dr. Marty Makary told Fox News Digital in a statement. ‘We’re addressing this critical issue by conducting a major modernization initiative on an accelerated timeline.’ 

‘Moving forward, the FDA will have a single, intuitive adverse event platform that will better equip us and any interested researcher to access key data and insights about the safety of products on the market,’ Makary added.

Adverse event reports are critical to determining the safety and effectiveness of certain drugs and products after they are approved for clinical trials and reach the wider consumer market, though the agency says the reports have been undermined due to current inefficient infrastructure.

The general concept of AEMS is that consumers will be able to access the new website and search for FDA-approved cosmetics, drugs, vaccines, or foods that have adverse effect reports as they are reported by healthcare professionals, consumers, manufacturers, and user facilities for medical devices. 

The agency estimates that roughly 6 to 7 million adverse event reports per year are evaluated through a seven database system. The FDA says that the collective cost of utilizing the database is an estimated $37 million bill to taxpayers. AEMS is expected to save the FDA approximately $120 million over the next five years, according to the agency.

The new website will be more accessible than the current quarterly report issued by the agency, and senior sources at the FDA told Fox News Digital they saw a 3,000% increase in users in a pilot program that launched last September.

‘Consolidating the FDA’s adverse event systems and converting to real-time publication was challenging, but made possible by a highly aggressive schedule,’ the FDA’s Chief AI Officer Jeremy Walsh told Fox News Digital in a statement. ‘The team executed with perfection and delivered the biggest technical transformation in agency history. This is the new FDA.’

The legacy systems that are currently in place include the FDA Adverse Event Reporting System (FAERS),  Vaccine Adverse Event Reporting System (VAERS), and Adverse Event Reporting System (AERS), which will be replaced with the new system effective immediately. 

In May, the AEMS will also replace the Manufacturer and User Facility Device Experience (MAUDE), Human Foods Complaint System (HFCS), and Center for Tobacco Products Adverse Event Reporting System (CTPAE).

Each one of these systems will be integrated into the new AEMS, with artificial intelligence assisting for manual data entries and coding adverse events. 

Sources at the FDA told Fox News Digital that the next phase of the rollout will be implementing a front-end system that makes it easy for reports to be submitted. The agency estimates that 80% of reports are never entered due to the complexity of filing a report — potentially resulting in some untold side effects never being made public. 

Preston Mizell is a writer with Fox News. Story tips can be sent to Preston.Mizell@fox.com and on X @MizellPreston

This post appeared first on FOX NEWS

previous post
Cornyn reverses on filibuster stance to push Trump’s SAVE Act in Senate
next post
171 million travelers face airport delays as Democrats’ DHS shutdown hits TSA staffing, Scalise warns

You may also like

US destroys 16 Iranian mine boats as Strait...

March 11, 2026

Iran, following Trump strikes, says ‘the doors of...

July 1, 2025

Putin signs revised doctrine lowering threshold for nuclear...

November 19, 2024

Iran’s Africa activities pose ‘significant threats to US...

July 28, 2025

Trump national security advisers mock Biden’s warnings to...

October 6, 2024

Trump orders Attorney General to investigate Biden’s autopen...

June 5, 2025

Influential leader of Canada’s Ontario province seeks Trump,...

January 12, 2025

Obama-era officials mum on allegations of ‘manufactured’ intelligence...

July 22, 2025

Supreme Court blocks Trump tariffs—but hands him a...

February 27, 2026

Trump-aligned super PAC enters 2026 midterms with nearly...

January 3, 2026

Recent Posts

  • Dem Senate primary erupts in key state as candidate teams up with radical streamer: ‘America deserved 9/11’
  • Trump-backed candidate aims to pad GOP’s fragile House majority battle in showdown for MTG’s seat
  • White House unleashes on Stacey Abrams in latest clash over Trump’s election order
  • Ilhan Omar calls Trump an ‘unhinged lunatic,’ urges booting him out of office
  • Former Virginia Gov Glenn Youngkin hints at political future, says he’s ‘chomping at the bit’ after exit

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (1,017)
    • Investing (4,320)
    • Politics (5,303)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 Sightful Invest. All Rights Reserved.